Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659360 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL338316 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1609987 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1611001 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL987954 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL77477 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL9121701 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL263776 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL988767 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1610778 | 1.00 | NR5A1 (0.60) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 756 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117964602-A | Benzothiophene ketone derivative and preparation method and application thereof | 广州医科大学 | 2024-05-03 | — | — | CN | claimed |
| CN-107442038-B | Ultraviolet response amino acid surfactant and preparation method thereof | 广州天赐高新材料股份有限公司 | 2019-08-09 | — | — | CN | claimed |
| CN-107442038-A | Ultraviolet response amino acid surfactant and preparation method thereof | 广州天赐高新材料股份有限公司 | 2017-12-08 | — | — | CN | claimed |
| US-7619055-B2 | Linked arylamine polymers and electronic devices generated therefrom | XEROX CORPORATION (US) | 2009-11-17 | — | — | US | claimed |
| US-20080194859-A1 | Polyurea Compositions and Compounds for the Preparation Thereof | Sawyer, Kenneth I. (US) | 2008-08-14 | — | — | US | claimed |
| EP-1282604-B1 | SUBSTITUTED CAPROLACTAM CARBONATES AND ETHERS AND THEIR USE AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | claimed |
| US-20070170398-A1 | Polypropylene resin compositions | SCHMIDT HANS-WERNER | 2007-07-26 | — | — | US | claimed |
| EP-1751206-A2 | POLYUREA COMPOSITIONS AND COMPOUNDS FOR THE PREPARATION THEREOF | Sawyer, Kenneth I. (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1087946-B1 | ARYL ALKANOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| EP-1366116-B1 | POLYPROPYLENE RESIN COMPOSITIONS | CIBA SC HOLDING AG (CH) | 2006-07-19 | — | — | EP | claimed |
| EP-1131297-A1 | CERTAIN SUBSTITUTED CAPROLACTAMS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN TREATING TUMORS | Novartis AG (CH) | 2001-09-12 | — | — | EP | claimed |
| US-6239220-B1 | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | claimed |
| US-6239127-B1 | CHEMOTHERAPY OF TUMORS, EXHIBIT A HIGH DEGREE OF SELECTIVITY IN KILLING CANCER CELLS. | NOVARTIS AG (CH) | 2001-05-29 | — | — | US | claimed |
| US-6124484-A | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-1005338-A1 | SUBSTITUTED AURONE DERIVATIVES | PHYTERA, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-2000029382-A1 | CERTAIN SUBSTITUTED CAPROLACTAMS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN TREATING TUMORS | NOVARTIS AG (CH) | 2000-05-25 | — | — | WO | claimed |
| WO-2000004062-A1 | RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| WO-1999004789-A1 | SUBSTITUTED AURONE DERIVATIVES | PHYTERA, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-0267585-B1 | FLUOROALKANE DERIVATIVE, ITS COMPOSITION AND LIQUID CRYSTAL DEVICE USING SAME | CANON KABUSHIKI KAISHA (JP) | 1993-09-15 | — | — | EP | claimed |
| US-4604471-A | PLASTIC STABILIZERS | BASF AKTIENGESELLSCHAFT (DE) | 1986-08-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194859-A1 | Polyurea Compositions and Compounds for the Preparation Thereof | PUF60, PCNA, PARG | NR5A1 4801/4885LTA4H 4166/4885TP53 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.